Cogent Biosciences reported positive phase 2 results for bezuclastinib, targeting non-advanced systemic mastocytosis. The drug achieved statistically significant improvements in symptom scores and mast cell burden, outperforming placebo. The company plans to file a New Drug Application (NDA) later this year, positioning bezuclastinib as a competitive candidate in mast cell disease treatment. Analyst comments have described the data as a 'home run scenario' highlighting potential market impact.